EU/3/17/1880

About

On 20 June 2017, orphan designation (EU/3/17/1880) was granted by the European Commission to ChemoCentryx Limited, United Kingdom, for avacopan (also known as CCX168 or (2R,3S)-2-(4-cyclopentylaminophenyl)-1-(2-fluoro-6-methylbenzoyl)piperidine-3-carboxylic acid(4-methyl-3-trifluoromethylphenyl)amide) for the treatment of C3 glomerulopathy.

The sponsorship was transferred to Chemocentryx Ireland Limited, Ireland, in February 2019.

Key facts

Active substance
Avacopan
Disease / condition
Treatment of C3 glomerulopathy
Date of decision
20/06/2017
Outcome
Positive
Orphan decision number
EU/3/17/1880

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Chemocentryx Ireland Limited
70 Sir John Rogerson's Quay
Dublin 2
Co. Dublin
Ireland
Tel: +353 1 232 2000
E-mail: regulatory@chemocentryx.com

 

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating